Clinical effect of lafutidine (Protecadin) on the mild case of Reflux Disease (health care economic comparison of which it contrasts Lansoprazole)

Clinical effect of lafutidine (Protecadin) on the mild case of Reflux Disease (health care economic comparison of which it contrasts Lansoprazole) - Clinical effect of lafutidine (Protecadin) on the mild case of Reflux Disease (health care economic comparison of which it contrasts Lansoprazole)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006162

Enrollment

160

Registered

2011-08-22

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

reflux esophagitis

Interventions

Lafutidine 20mg after breakfast and supper(or at bedtime)(eight weeks) Lansoprazole 30mg after breakfast(eight weeks)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patient diagnosed as LA classification Grade A by endoscopy within seven days before start of the study 2)Patient whose either score of question 2 or question 3 on GSRS interview sheet is three or more when study is registered

Exclusion criteria

Exclusion criteria: 1)Patient with gastroduodenal ulcer (ulcer scar is assumed to be acceptable) and cancer of upper gastroitestinal tract 2)Patient with barett's epithelium extends it to part by ..distal portion of esophagus.. exceed 3cm 3)Patient with past history of operation of upper gastrointestinal tract 4)Patient who had taken PPI and H2RA within 2weeks before endscopy 5)Severe disease in heart, liver and kidney 6)Drug allergy for laftidine, lansoprazole and other drugs 7)expectant mother, mother with breast-feeding 8)other not applicable person recognized by a doctor

Design outcomes

Primary

Measure	Time frame
evaluation of the change of degree of symptoms of patients after eight weeks of PPI or H2RA administering	—

Secondary

Measure	Time frame
evaluation of the change of symptoms of patients until 24 weeks after administration PPI or H2RA	—

Countries

Japan

Contacts

Public ContactKenji Furuta

Shimane University Faculty of Medicine Second Department of Internal Medicine

0853-20-2190

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026